drugset / Trial / NCT00219297

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

NCT00219297

Phase 2 Completed 50 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after chemotherapy, surgery and/or radiation.

Timeline

Start
2005-11-16
Primary completion
2010-06-24
Completion
2010-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule